Welcome to our dedicated page for Nano-X Imaging news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging stock.
NANO-X IMAGING LTD reports news on an integrated medical imaging and healthcare services platform built around Nanox.ARC multisource digital tomosynthesis systems, AI and software solutions, cloud-based workflow tools, remote radiology access, health information technology and a marketplace model. Company updates commonly cover U.S. commercialization, distribution agreements, clinical collaborations and regulatory clearances tied to Nanox.ARC and related imaging capabilities.
Recurring financial and operating news also includes results from teleradiology services, imaging products and services, AI and software activity, and the completed addition of Nanox Health IT. The company frames its commercial activity around broader access to 3D imaging and preventive-care workflows across clinical settings.
Nanox (NASDAQ:NNOX) reported third-quarter 2025 results and a business update on November 20, 2025. The company generated $3.4M revenue in Q3 2025 versus $3.0M year-ago, and reported a GAAP net loss of $13.7M for the quarter. Gross loss was $2.9M (GAAP) and non-GAAP gross loss was $0.3M. Nanox completed the acquisition of Vaso Healthcare IT, added clinical sites including Cedars-Sinai and Olympe Imagerie, and signed European ARC distribution partnerships. Cash and equivalents totaled $55.5M as of September 30, 2025, and the company expects >100 deployed units by year-end 2025 and $35M revenue for 2026.
Nanox (Nasdaq: NNOX) agreed to acquire VasoHealthcare IT Inc. from Vaso (OTCQX: VASO) to accelerate U.S. deployment of its AI imaging solutions. The transaction is expected to close within a couple of weeks and integrates VHC IT’s implementation, systems integration, workflow optimization, data migration, user training, and nationwide go-live support with Nanox.AI’s FDA-cleared CT-scan AI tools.
Consideration is up to $800,000: $200,000 cash at closing plus up to $600,000 in performance-based earnouts over two years contingent on revenue retention of existing customers.
Nanox (NASDAQ: NNOX) announced a collaboration with Paris-based radiology group Olympe Imagerie to deploy the Nanox.ARC at Hospital Privé Jacques Cartier MASSY for lung cancer screening clinical trials, dated Nov 14, 2025. The Nanox.ARC, a multi-source digital tomosynthesis system, received its CE Mark in February 2025 and is cleared for commercialization across the EU. The deployment advances Nanox’s European clinical validation program and commercial presence. Olympe Imagerie’s centers collectively serve more than 400,000 outpatients, inpatients, and visitors annually, offering significant clinical exposure for trial activities.
Nanox (Nasdaq: NNOX) will launch and demonstrate the FDA 510(k)-cleared Nanox.ARC X multi-source digital tomosynthesis system at RSNA 2025 (Nov 30–Dec 4, 2025) in Chicago. The Nanox.ARC X received FDA clearance in April 2025 for musculoskeletal, pulmonary, intra-abdominal and paranasal indications and is described as lower cost and lower radiation than CT. Live demos run every 30 minutes at Booth #3914. The company will also present clinical data, unveil a pulmonary nodule AI under development, and introduce two new AI tools for aortic valve calcification and body composition measurement.
Nanox (Nasdaq: NNOX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 20, 2025 before market open. Management will host a conference call and live webcast on the same day at 8:30 a.m. ET to review results and provide a business update. Registration and the live webcast will be available via the company website in the Investor Relations Events and Presentations section.
NANO-X IMAGING (Nasdaq: NNOX) on November 6, 2025 announced a distribution agreement with Czech imaging distributor EXRAY to introduce the Nanox.ARC multi-source digital tomosynthesis system across the Czech Republic.
EXRAY, founded in 2013, has installations in >50% of the country’s ~200 healthcare facilities and will lead market introduction, sales and service. The Nanox.ARC holds a CE Mark clearance for commercialization across the European Union.
Nanox (NASDAQ:NNOX) has announced a strategic collaboration with Monarch Medical Management and Billing LLC to deploy advanced medical imaging solutions across multiple healthcare segments. The partnership will establish a comprehensive imaging network initially spanning over a dozen proof-of-concept sites, with plans for nationwide expansion.
The collaboration will integrate Nanox's technology, including the Nanox.ARC 3D digital tomosynthesis system, AI-powered software for CT scan analysis, and teleradiology services across workers' compensation facilities, nursing homes, and outpatient clinics. This initiative aims to improve access to advanced imaging services and accelerate diagnosis and treatment decisions.
Nanox (NASDAQ: NNOX), a medical imaging technology company, reported its Q2 2025 financial results with revenue of $3.0 million, up from $2.7 million in Q2 2024. The company posted a net loss of $14.7 million, compared to $13.6 million in the prior year period.
Key developments include growing the Nanox.ARC system sales pipeline, plans to submit the TAP2D software module to FDA for 510(k) clearance, and a new partnership with Fabrinet for manufacturing support. The company expanded its presence in the U.S. and EU markets, with new customers including major imaging center chains and progress in Romania.
Nanox maintains its target of deploying over 100 units worldwide by end of 2025. As of June 30, 2025, the company held $62.6 million in cash and equivalents, down from $83.5 million at the end of 2024.
Nanox (NASDAQ:NNOX), a medical imaging technology company, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, before market open.
The company will host a conference call at 8:30 a.m. ET featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel, who will review the results and provide a business update. Investors can access the presentation through a live webcast available on the company's Investor Relations website.
Nanox (NASDAQ:NNOX) has announced a strategic clinical and educational collaboration with Keiser University to deploy its advanced Nanox.ARC 3D digital tomosynthesis imaging system at the university's Sarasota Campus. The system will be used for training healthcare professionals and will be incorporated into Keiser's Radiologic Technology graduate program.
The Nanox.ARC features a proprietary digital X-ray source and cold cathode technology, providing enhanced 3D imaging capabilities. Clinical studies have demonstrated the system's improved sensitivity and specificity compared to traditional X-ray, while achieving reduced radiation exposure and shorter radiologist reading times compared to CT scans.
The collaboration with Keiser University, which has awarded approximately 100,000 degrees and operates 19 Florida campuses, aims to educate prospective users about the Nanox.ARC's clinical value and increase the usage of various clinical protocols for patient benefit.